Navigation Links
Talecris Biotherapeutics Enrolls Patients in Clinical Trial Evaluating Two Doses of PROLASTIN®-C
Date:12/9/2010

"augments" protein levels in AAT deficient patients.   In the U.S. and Canada, PROLASTIN-C has replaced PROLASTIN, the leading augmentation therapy in North America for more than 20 years.  

Important Safety Information for PROLASTIN-C

The effect of augmentation therapy with any alpha(1)-proteinase inhibitor on pulmonary exacerbations and on the progression of emphysema in alpha(1)-antitrypsin deficiency has not been demonstrated in randomized, controlled clinical trials.

PROLASTIN-C may contain trace amounts of IgA.  Patients with known antibodies to IgA, which can be present in patients with selective or severe IgA deficiency, have a greater risk of developing potentially severe hypersensitivity and anaphylactic reactions.  PROLASTIN-C is contraindicated in patients with antibodies against IgA.

The most common drug related adverse reactions during clinical trials in greater than or equal to 1% of subjects were chills, malaise, headache, rash, hot flush, and pruritus.  The most serious adverse reaction observed during the clinical studies with PROLASTIN-C was an abdominal and extremity rash in one subject.

PROLASTIN-C is made from human plasma. Products made from human plasma may carry a risk of transmitting infectious agents, e.g., viruses, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent.

In the US, for additional information on PROLASTIN-C, please see full prescribing information at www.PROLASTIN.com.  You are encouraged to report negative side effects of prescription drugs to the FDA.  Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

About Alpha(1)-Antitrypsin Deficiency

Alpha(1)-antitrypsin deficiency, also known as AAT deficiency or Alpha-1, is an inherited disorder that causes significant reduction in the naturally occurring protein alpha(1)-proteina
'/>"/>

SOURCE Talecris Biotherapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Talecris Biotherapeutics Launches PROLASTIN®-C in Canada
2. Talecris Biotherapeutics Receives FDA Approval for Gamunex®-C
3. Talecris Biotherapeutics to Report Third Quarter 2010 Financial Results
4. Talecris Biotherapeutics CEO Accepts 2010 Ernst & Young Entrepreneur Of The Year Award on Behalf of Employees and Patients
5. Talecris Forms Partnership to Co-Promote Life-Saving Rabies Products
6. Talecris Biotherapeutics Receives FDA Approval for PROLASTIN(R)-C
7. Protalix BioTherapeutics Announces Preliminary Top-Line Positive Data from taliglucerase alfa Switchover Trial
8. Protalix BioTherapeutics to Present at Two Upcoming Healthcare Conferences
9. Garnet BioTherapeutics Announces First Patient Treated in Trial of New Therapy for Improvement in Scar Appearance
10. NASDAQ Trading for Oxygen Biotherapeutics, Inc. Shares to Begin January 15, 2010
11. Oxygen Biotherapeutics, Inc. Announces Approval for NASDAQ Listing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2015)... , Mar. 27, 2015 Research and ... the addition of the "European Laboratory Information ... System), by Type (Clinical Pathology Laboratory Information System, ... 2019" report to their offering. ... to grow at a CAGR of 7.6% from ...
(Date:3/31/2015)... N.J. , March 31, 2015  PAION, ... today announced the initiation of a U.S. Phase ... for procedural sedation in patients undergoing colonoscopy. ... faster onset of sedation and greater procedural success ... profile and patients experienced rapid recovery from sedation ...
(Date:3/30/2015)... , 31 mars 2015  Une équipe de scientifiques ... atomique d,un récepteur de surface cellulaire qui ... de thromboses. Contre toute attente, cette recherche ... caractéristiques structurelles qui remettent en cause les ... les récepteurs couplés aux protéines G (RCPG) ...
Breaking Medicine Technology:European Laboratory Information System Market Report 2015: Germany holds a larger share of the laboratory information systems market 2European Laboratory Information System Market Report 2015: Germany holds a larger share of the laboratory information systems market 3PAION Announces Initiation of U.S. Phase 3 Clinical Trial of Remimazolam for Procedural Sedation During Colonoscopy 2PAION Announces Initiation of U.S. Phase 3 Clinical Trial of Remimazolam for Procedural Sedation During Colonoscopy 3PAION Announces Initiation of U.S. Phase 3 Clinical Trial of Remimazolam for Procedural Sedation During Colonoscopy 4De nouvelles structures moléculaires remettent en cause les idées conventionnelles concernant l'action des médicaments sur les récepteurs 2De nouvelles structures moléculaires remettent en cause les idées conventionnelles concernant l'action des médicaments sur les récepteurs 3
... ,, BETHESDA, Md. , June 30 ... an innovator in biotechnology for therapy in diabetes, ... and regulatory consulting services to food, supplement, biotechnology ... subsidiary, Biospherics Incorporated, has signed a license agreement ...
... 30 Xoft, the leading provider of FDA-cleared ... Center of Hoag Memorial Hospital Presbyterian in Newport ... Brachytherapy, eBx™ System to support the launch of its ... progressive, comprehensive approach to breast cancer treatment. The first ...
Cached Medicine Technology:Biospherics Acquires Global Patent Rights from University of Kentucky Research Foundation to Develop Tagatose as a Trigylcerides Therapy 2Biospherics Acquires Global Patent Rights from University of Kentucky Research Foundation to Develop Tagatose as a Trigylcerides Therapy 3Biospherics Acquires Global Patent Rights from University of Kentucky Research Foundation to Develop Tagatose as a Trigylcerides Therapy 4Biospherics Acquires Global Patent Rights from University of Kentucky Research Foundation to Develop Tagatose as a Trigylcerides Therapy 5Hoag Breast Care Center Installs Xoft Electronic Brachytherapy System for IORT Program 2Hoag Breast Care Center Installs Xoft Electronic Brachytherapy System for IORT Program 3Hoag Breast Care Center Installs Xoft Electronic Brachytherapy System for IORT Program 4
(Date:3/31/2015)... (PRWEB) March 31, 2015 Horizon Blue ... today that its efforts to combat health insurance fraud ... a combination of monies recovered and losses avoided -- ... total since Horizon BCBSNJ created its fraud fighting, Special ... BCBSNJ’s anti-fraud efforts have saved members $261 million. ...
(Date:3/31/2015)... An individual’s meniscus (cushion in the knee) ... leg providing stability, load bearing and preservation of the ... Day meeting of the American Orthopaedic Society for Sports ... the potential for biologic healing following a meniscus tear. ... of meniscus tears when a root repair is performed ...
(Date:3/31/2015)... 2015 Burns Engineering announces 3-Day Quick Ship ... the Food & Beverage, Pharmaceutical and Biotech markets. These field ... compliant and are now available as part of Burns’ Quick ... The S01 and S03 with 1/8” and 1/4” ... connections used in process lines 1/4” and larger. Sensors ...
(Date:3/31/2015)... The report “Coagulation/Hemostasis Analyzer Market By ... (APTT, Prothrombin Time/INR, D-Dimer, Fibrinogen), Technology (Mechanical, Optical), ... and studies the major market drivers, restraints, opportunities ... the Rest of the world (RoW). , ... reach $3.58 billion by 2019 from $2.4 billion ...
(Date:3/31/2015)... March 31, 2015 DentalXChange, ... specializes in providing online solutions to connect ... it has achieved full accreditation for the ... Accreditation Program (HNAP) from the Electronic Healthcare ... HNAP accreditation runs in two-year increments and ...
Breaking Medicine News(10 mins):Health News:Horizon Blue Cross Blue Shield of New Jersey Saves Members, Health System a Record $45.4 Million through Anti-fraud Efforts 2Health News:New Way to Evaluate Meniscus Tear Outcomes 2Health News:Burns Engineering Now Offers 3-Day Quick Ship on Sanitary RTDs and Thermocouples 2Health News:The Global Coagulation Analyzers Market will be Valued at $3.58 Billion in 2019 - MarketsandMarkets 2Health News:The Global Coagulation Analyzers Market will be Valued at $3.58 Billion in 2019 - MarketsandMarkets 3Health News:The Global Coagulation Analyzers Market will be Valued at $3.58 Billion in 2019 - MarketsandMarkets 4Health News:DentalXChange Achieves EHNAC Healthcare Network Accreditation for Fifth Consecutive Time 2Health News:DentalXChange Achieves EHNAC Healthcare Network Accreditation for Fifth Consecutive Time 3
... HealthDay Reporter , MONDAY, Dec. 12 (HealthDay News) -- Toddlers ... finding that researchers say may provide a clue to the ... is largely an involuntary process that helps keep the eyes ... are closed, you are temporarily blinded. And throughout a typical ...
... infrastructure, inefficient distribution channels and disruptive black markets must ... with the growing problem of malaria, according to a ... Systems and Management . Historically, malaria is humanity,s ... some regions it remains the biggest infectious threat in ...
... , MONDAY, Dec. 12 (HealthDay News) -- Acupuncture may ... according to a new study. Cancer drugs called ... nerves, especially in the calves and feet, resulting in ... is no effective treatment for the condition, called chemotherapy ...
... Reporter , MONDAY, Dec. 12 (HealthDay News) -- When she was ... Madeline Mann was the world,s smallest surviving baby. At the ... world,s tiniest infant, weighing in at 0.57 pounds. She was one ... the neonatal intensive care unit at Loyola University Medical Center in ...
... Reinberg HealthDay Reporter , MONDAY, Dec. 12 ... colon, breast, prostate and cervical cancer even though guidelines ... finds. As the population of the United States ... will be a continuing battle, experts say. "In an ...
... Patients who receive a blood ... to treat leukemia and other blood diseases are more likely ... disease, a condition caused by the donor cells attacking the ... a donor,s bone marrow, rather than from blood stem cells ...
Cached Medicine News:Health News:Blink Patterns May Be a Window Into Autistic Mind 2Health News:Blink Patterns May Be a Window Into Autistic Mind 3Health News:A logistics approach to malaria in Africa 2Health News:Acupuncture Might Ease Chemotherapy Pain 2Health News:World's Tiniest 'Preemies' Growing Up Healthy: Report 2Health News:World's Tiniest 'Preemies' Growing Up Healthy: Report 3Health News:Are Too Many Older People Screened for Cancer? 2Health News:Are Too Many Older People Screened for Cancer? 3Health News:Bone marrow and blood stem cell transplant survival rates equal, when donor is unrelated to patient 2
The ExcaliburPlus PC is the most powerful isolated ESU with 10,000 V PTP in spray coag....
Elmed BC 50 M/M is an all purpose bipolar coagulator with a macro and micro mode. In the micro mode, the unit is ideally suitable for wet-field coagulation in ophthalmology, neurosurgery and other mi...
...
...
Medicine Products: